XOMA Royalty (XOMA) Competitors $37.59 +0.85 (+2.31%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$37.56 -0.04 (-0.09%) As of 09/18/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, MNKD, CLDX, INVA, NVAX, DVAX, OPK, GERN, ZBIO, and RIGLShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), MannKind (MNKD), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA MannKind Celldex Therapeutics Innoviva Novavax Dynavax Technologies OPKO Health Geron Zenas BioPharma Rigel Pharmaceuticals XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment. Do analysts recommend XOMAO or XOMA? XOMA Royalty has a consensus target price of $69.50, indicating a potential upside of 84.89%. Given XOMA Royalty's stronger consensus rating and higher possible upside, analysts clearly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is XOMAO or XOMA more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMAN/A N/A N/A XOMA Royalty -27.57%2.63%0.97% Do insiders & institutionals believe in XOMAO or XOMA? 95.9% of XOMA Royalty shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, XOMAO or XOMA? XOMA has higher earnings, but lower revenue than XOMA Royalty. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$12.77MN/AN/AN/AN/AXOMA Royalty$28.49M15.95-$13.82M-$1.55-24.25 Does the media prefer XOMAO or XOMA? In the previous week, XOMA Royalty had 5 more articles in the media than XOMA. MarketBeat recorded 6 mentions for XOMA Royalty and 1 mentions for XOMA. XOMA Royalty's average media sentiment score of 0.77 beat XOMA's score of -0.50 indicating that XOMA Royalty is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative XOMA Royalty 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryXOMA Royalty beats XOMA on 11 of the 12 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$444.10M$3.12B$5.78B$10.27BDividend YieldN/A2.37%5.74%4.64%P/E Ratio-24.2521.3676.5226.98Price / Sales15.95479.50546.03182.41Price / CashN/A45.3237.1760.63Price / Book5.419.6913.886.37Net Income-$13.82M-$52.92M$3.29B$271.46M7 Day Performance0.45%2.19%1.60%2.53%1 Month Performance17.25%8.96%6.89%9.42%1 Year Performance25.93%10.84%82.40%30.16% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.271 of 5 stars$37.59+2.3%$69.50+84.9%+31.2%$444.10M$28.49M-24.2510XOMAOXOMAN/A$25.52+0.1%N/A+1.4%$0.00$12.77M0.0010News CoverageShort Interest ↑MNKDMannKind4.4018 of 5 stars$5.57+0.5%$10.71+92.4%-15.8%$1.70B$285.50M50.64400Positive NewsAnalyst ForecastInsider TradeShort Interest ↓CLDXCelldex Therapeutics2.2086 of 5 stars$23.40+2.3%$46.67+99.4%-38.1%$1.52B$7.02M-7.77150Analyst ForecastGap UpINVAInnoviva4.8496 of 5 stars$20.46-0.1%$42.75+108.9%+1.8%$1.29B$358.71M66.00100Positive NewsShort Interest ↓NVAXNovavax4.2327 of 5 stars$7.73-2.2%$14.29+84.8%-32.1%$1.28B$1.08B3.391,990DVAXDynavax Technologies4.4106 of 5 stars$9.70-3.6%$24.33+150.9%-13.0%$1.18B$316.27M-21.09350Positive NewsOPKOPKO Health4.3866 of 5 stars$1.42+5.2%$2.75+93.7%-6.8%$1.07B$713.10M-5.682,997GERNGeron3.1871 of 5 stars$1.37-2.1%$4.19+205.7%-70.8%$893.22M$164.45M-10.5470Positive NewsGap UpZBIOZenas BioPharma1.1591 of 5 stars$21.51+4.9%$36.67+70.5%N/A$863.68M$5M-6.06N/AHigh Trading VolumeRIGLRigel Pharmaceuticals2.5315 of 5 stars$40.87-1.1%$38.20-6.5%+157.6%$741.53M$179.28M7.55160Positive News Related Companies and Tools Related Companies XOMA Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Innoviva Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Zenas BioPharma Alternatives Rigel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
